Standard
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes : a cohort study. / Castagliola, Dominique; Ledergerber, Bruno; Torti, Carlo; van Sighem, Ard; Podzamczer, Daniel; Mocroft, Amanda; Dorrucci, Maria; Masquelier, Bernard; de Luca, Andrea; Jansen, Klaus; De Wit, Stephane; Obel, Niels; Fätkenheuer, Gerd; Touloumi, Giota; Mussini, Cristina; Castagna, Antonella; Stephan, Cristoph; Garcia, Frederico; Zangerle, Robert; Duval, Xavier; Pérez-Hoyos, Santiago; Meyer, Laurence; Ghosn, Jade; Fabre-Colin, Céline; Kjaer, Jesper; Chene, Genevieve; Costagliola, Dominque; Lodwick, Rebecca; Phillips, Andrew; Pursuing Later Treatment Option II (PLATO II) project team.
I:
Lancet Infectious Diseases, Bind 12, Nr. 2, 2012, s. 119-27.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Castagliola, D, Ledergerber, B, Torti, C, van Sighem, A, Podzamczer, D, Mocroft, A, Dorrucci, M, Masquelier, B, de Luca, A, Jansen, K, De Wit, S
, Obel, N, Fätkenheuer, G, Touloumi, G, Mussini, C, Castagna, A, Stephan, C, Garcia, F, Zangerle, R, Duval, X, Pérez-Hoyos, S, Meyer, L, Ghosn, J, Fabre-Colin, C, Kjaer, J, Chene, G, Costagliola, D, Lodwick, R, Phillips, A & Pursuing Later Treatment Option II (PLATO II) project team 2012, '
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study',
Lancet Infectious Diseases, bind 12, nr. 2, s. 119-27.
https://doi.org/10.1016/S1473-3099(11)70248-1APA
Castagliola, D., Ledergerber, B., Torti, C., van Sighem, A., Podzamczer, D., Mocroft, A., Dorrucci, M., Masquelier, B., de Luca, A., Jansen, K., De Wit, S.
, Obel, N., Fätkenheuer, G., Touloumi, G., Mussini, C., Castagna, A., Stephan, C., Garcia, F., Zangerle, R., ... Pursuing Later Treatment Option II (PLATO II) project team (2012).
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.
Lancet Infectious Diseases,
12(2), 119-27.
https://doi.org/10.1016/S1473-3099(11)70248-1Vancouver
Castagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A o.a.
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.
Lancet Infectious Diseases. 2012;12(2):119-27.
https://doi.org/10.1016/S1473-3099(11)70248-1Author
Castagliola, Dominique ; Ledergerber, Bruno ; Torti, Carlo ; van Sighem, Ard ; Podzamczer, Daniel ; Mocroft, Amanda ; Dorrucci, Maria ; Masquelier, Bernard ; de Luca, Andrea ; Jansen, Klaus ; De Wit, Stephane ; Obel, Niels ; Fätkenheuer, Gerd ; Touloumi, Giota ; Mussini, Cristina ; Castagna, Antonella ; Stephan, Cristoph ; Garcia, Frederico ; Zangerle, Robert ; Duval, Xavier ; Pérez-Hoyos, Santiago ; Meyer, Laurence ; Ghosn, Jade ; Fabre-Colin, Céline ; Kjaer, Jesper ; Chene, Genevieve ; Costagliola, Dominque ; Lodwick, Rebecca ; Phillips, Andrew ; Pursuing Later Treatment Option II (PLATO II) project team. / Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes : a cohort study. I: Lancet Infectious Diseases. 2012 ; Bind 12, Nr. 2. s. 119-27.
Bibtex
@article{1fa3fc6c77fe4ab5b20b51254696aa85,
title = "Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study",
abstract = "Limited treatment options have been available for people with HIV who have had virological failure of the three original classes of HIV antiretroviral drugs-so-called triple-class virological failure (TCVF). However, introduction of new drugs and drug classes might have improved outcomes. We aimed to assess trends in virological and clinical outcomes for individuals with TCVF in 2000-09.",
author = "Dominique Castagliola and Bruno Ledergerber and Carlo Torti and {van Sighem}, Ard and Daniel Podzamczer and Amanda Mocroft and Maria Dorrucci and Bernard Masquelier and {de Luca}, Andrea and Klaus Jansen and {De Wit}, Stephane and Niels Obel and Gerd F{\"a}tkenheuer and Giota Touloumi and Cristina Mussini and Antonella Castagna and Cristoph Stephan and Frederico Garcia and Robert Zangerle and Xavier Duval and Santiago P{\'e}rez-Hoyos and Laurence Meyer and Jade Ghosn and C{\'e}line Fabre-Colin and Jesper Kjaer and Genevieve Chene and Dominque Costagliola and Rebecca Lodwick and Andrew Phillips and Niels Obel",
note = "Copyright {\textcopyright} 2012 Elsevier Ltd. All rights reserved.",
year = "2012",
doi = "10.1016/S1473-3099(11)70248-1",
language = "English",
volume = "12",
pages = "119--27",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "TheLancet Publishing Group",
number = "2",
}
RIS
TY - JOUR
T1 - Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes
T2 - a cohort study
AU - Castagliola, Dominique
AU - Ledergerber, Bruno
AU - Torti, Carlo
AU - van Sighem, Ard
AU - Podzamczer, Daniel
AU - Mocroft, Amanda
AU - Dorrucci, Maria
AU - Masquelier, Bernard
AU - de Luca, Andrea
AU - Jansen, Klaus
AU - De Wit, Stephane
AU - Obel, Niels
AU - Fätkenheuer, Gerd
AU - Touloumi, Giota
AU - Mussini, Cristina
AU - Castagna, Antonella
AU - Stephan, Cristoph
AU - Garcia, Frederico
AU - Zangerle, Robert
AU - Duval, Xavier
AU - Pérez-Hoyos, Santiago
AU - Meyer, Laurence
AU - Ghosn, Jade
AU - Fabre-Colin, Céline
AU - Kjaer, Jesper
AU - Chene, Genevieve
AU - Costagliola, Dominque
AU - Lodwick, Rebecca
AU - Phillips, Andrew
AU - Pursuing Later Treatment Option II (PLATO II) project team
N1 - Copyright © 2012 Elsevier Ltd. All rights reserved.
PY - 2012
Y1 - 2012
N2 - Limited treatment options have been available for people with HIV who have had virological failure of the three original classes of HIV antiretroviral drugs-so-called triple-class virological failure (TCVF). However, introduction of new drugs and drug classes might have improved outcomes. We aimed to assess trends in virological and clinical outcomes for individuals with TCVF in 2000-09.
AB - Limited treatment options have been available for people with HIV who have had virological failure of the three original classes of HIV antiretroviral drugs-so-called triple-class virological failure (TCVF). However, introduction of new drugs and drug classes might have improved outcomes. We aimed to assess trends in virological and clinical outcomes for individuals with TCVF in 2000-09.
U2 - 10.1016/S1473-3099(11)70248-1
DO - 10.1016/S1473-3099(11)70248-1
M3 - Journal article
VL - 12
SP - 119
EP - 127
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
SN - 1473-3099
IS - 2
ER -
